Ivermectin inhibits AR pathway in prostate cancer models. Resistance to AR pathway inhibitors in prostate cancer is associated with AR amplification, mutations, and expression of truncated AR variants, the latter characterized by loss of AR’s ligand-binding domain and constitutively active transcription
https://truthsocial.com/@FloridaSharkman/posts/108771884544011965